AMRI has entered a multi-year research collaboration with Navigen Pharmaceuticals focused on the development of new drug therapies. AMRI will provide drug discovery services including assay development, screening, in vitro ADMET, computer-aided drug discovery (CADD) and medicinal chemistry. “AMRI has a proven track record of success working with biotech companies such as Navigen,” said Michael P. Trova, Ph.D., senior vice president, chemistry. “Our ability to execute integrated biology and ch...